Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BORTEZOMIB Cause Malignant neoplasm progression? 375 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 375 reports of Malignant neoplasm progression have been filed in association with BORTEZOMIB (bortezomib). This represents 0.8% of all adverse event reports for BORTEZOMIB.

375
Reports of Malignant neoplasm progression with BORTEZOMIB
0.8%
of all BORTEZOMIB reports
176
Deaths
115
Hospitalizations

How Dangerous Is Malignant neoplasm progression From BORTEZOMIB?

Of the 375 reports, 176 (46.9%) resulted in death, 115 (30.7%) required hospitalization, and 24 (6.4%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for BORTEZOMIB. However, 375 reports have been filed with the FAERS database.

What Other Side Effects Does BORTEZOMIB Cause?

Plasma cell myeloma (6,683) Off label use (4,754) Neuropathy peripheral (4,067) Drug ineffective (2,730) Diarrhoea (2,244) Thrombocytopenia (2,082) Death (2,025) Pneumonia (2,020) Fatigue (1,757) Neutropenia (1,530)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which BORTEZOMIB Alternatives Have Lower Malignant neoplasm progression Risk?

BORTEZOMIB vs BOSENTAN BORTEZOMIB vs BOSENTAN\BOSENTAN BORTEZOMIB vs BOSULIF BORTEZOMIB vs BOSUTINIB BORTEZOMIB vs BOTOX

Related Pages

BORTEZOMIB Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression BORTEZOMIB Demographics